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Background and Objectives. The incidence of invasive
filamentous fungal infections in hematologic patients is
increasing as a consequence of high dose chemotherapy
and bone marrow transplant procedures. Mortality is usu-
ally very high. The diagnosis is often difficult and yet a
fast, accurate diagnosis is of fundamental importance for
treating the infection and planning subsequent manage-
ment of the hematologic disease. We evaluated the sen-
sitivity of computed tomography (CT)-guided percuta-
neous biopsy in diagnosing pulmonary fungal infections.
Design and Methods. Between 1997 and 2002 we
performed 17 CT-guided percutaneous transthoracic lung
biopsies in 17 hematologic patients with suspected fila-
mentous fungi infection with negative BAL, to obtain a
certain diagnosis and to know what species of fungi was
responsible for infection. In all cases suspected mycosis
began during the post-chemotherapy aplastic period.
Patients were receiving antifungal therapy at the time of
all biopsies. When the platelet count rose above
50×109/L, CT-guided percutaneous lung biopsy with fine-
needle aspiration for cytology was performed.
Results. Twelve of 17 patients had histologic confir-
mation of the fungal infection (70.5%), 8 with Aspergillus
spp. 4 with Mucorales spp. Biopsies provided non-specific
results in 4 cases; in 2 of these cases, clinical course and
response to therapy confirmed the diagnosis of mycosis;
in the last case bronchoalveolar carcinoma was found as
a new diagnosis. Cultures were positive in only 6 cases,
all for Aspergillus spp. The sensitivity of CT-guided per-
cutaneous lung biopsy was 70.6% and its positive pre-
dictive value (PPV) was 100%. This procedure provided an
immediate diagnosis and only one side-effect (1 pneu-
mothorax, without complications).
Interpretation and Conclusions. Histologic discrimi-
nation between aspergillosis and mucormycosis is very
important for deciding secondary prophylaxis during
transplant procedures, because Mucor is usually resis-
tant to azoles.




©2003, Ferrata Storti Foundation
Utility of percutaneous lung biopsy for diagnosing filamentous fungal infections in
hematologic malignancies
ANNAMARIA NOSARI, MICHELA ANGHILIERI, GIANPAOLO CARRAFIELLO, CLEOFE GUFFANTI, LAURA MARBELLO, MARCO MONTILLO, GIULIANA MUTI,
SONIA RIBERA, ALBERTO VANZULLI, MICHELE NICHELATTI, ENRICA MORRA
The presence of invasive filamentous fungal infec-tions is increasing in hematologic patients, due tohigh dose chemotherapy and bone marrow trans-
plant procedures.1 Mortality is usually very high, par-
ticularly in recipients of bone marrow transplants.2
The diagnosis is very difficult in neutropenic patients
because cultures are often negative and diagnosis can
only be said to be probable. Nevertheless, it is important
to confirm the fungal etiology of pulmonary lesions,
which are defined probable aspergillosis, and also to
determine the causative fungal species. Prolonged anti-
fungal treatment, correct secondary prophylaxis  and a
possible subsequent decision about pulmonary resection
can be indispensable in scheduling bone marrow trans-
plantation in leukemic patients.3,4 In these patients
computed tomography (CT) scanning of the chest,  per-
formed early, is very useful to identify a probable pul-
monary aspergillosis by detecting the presence of the
halo sign and air crescent sign which are characteristic
of fungal infection.3 Bronchoalveolar lavage (BAL) is
usually performed in these patients, but the sensitivity
of this method in detecting aspergillosis is only 50%
according to some authors5 and also in our experience.4
These bronchoscopic procedures may detect coloniza-
tion but not invasion from fungi. Transbronchial biop-
sy, performed only when the platelet count is
> 50×109/L, improves the diagnostic accuracy by only
6.5%.5 There are, therefore, many patients in whom the
diagnosis of mycosis must simply be considered possi-
ble, and only the clinical course helps in the choice of
therapy; every diagnostic procedure that converts a pos-
sible mycotic infection to a probable or proven one is
useful for programming the following therapies. 
In the last six years (1997-2002), we performed per-
cutaneous lung biopsy in hematologic patients with a
pulmonary picture of filamentous fungal infection with
negative BAL, in order to obtain a certain diagnosis and
to identify the species of fungi that was responsible for
the infection.
Design and Methods 
We retrospectively reviewed the results of 17 CT-
guided percutaneous lung biopsies from hematologic
patients (13 with acute myeloid leukemia, 1 with acute
lymphoid leukemia, 2 with non-Hodgkin’s lymphoma,
and 1 with aplastic anemia) performed between 1997-
2002.
Microbiological surveillance cultures (nose, throat,
From the Depts. of Hematology (AN, MA, LM, MM, GM, SR, MN, EM), Pathology
(CG), Radiology (AV, GC) Niguarda Ca’ Granda Hospital, Milan, Italy.
Correspondence: Annamaria Nosari, MD, Division of Haematology,
Dept. of Oncology and Hematology, Niguarda Ca’ Granda Hospital,
Piazza Ospedale Maggiore 3, 20162 Milan, Italy. E-mail: miccaimi@tin.it
1406 haematologica/journal of hematology vol. 88(12):december 2003
stools and vagina) were performed every week dur-
ing the post-chemotherapy period of aplasia. All
patients were receiving antifungal prophylaxis with
oral itraconazole 300 mg/day. Empirical antifungal
therapy (amphotericin B deoxycholate 1
mg/Kg/day) was begun in febrile neutropenic
patients who did not respond to broad-spectrum
antibiotic therapy and had negative cultures or in
patients with persistent neutropenia who had a
subsequent episode of fever with negative cultures.
Liposomal amphotericin (Ambisome) was adminis-
tered if the patient’s creatinine concentration was
> 2 mg/dL. As reported in literature3 early high
resolution CT scan was performed to identify pos-
sible fungal infection; BAL was also usually done as
soon as possible. If the BAL was negative for fun-
gi, when platelet count rose above  50×109/L, CT-
guided percutaneous lung biopsy with fine-needle
aspiration for cytology was performed, preferably
on peripheral lesions.6,7 A 22-gauge needle was
preferred to minimize the risk of pneumothorax;
the median number of passes taken to pleura was
3 (range 2-5), sufficient to ensure an adequate
specimen. Aspirated material was immediately
inspected by a pathologist to judge the adequacy
of the sample and was then usually immediately
fixed in 10% formalin solution. The hyphae were
visualized in tissue sections stained with periodic
acid-Schiff reaction or Grocott-Gomori
methanamine-silver nitrate. A histologic diagnosis
of aspergillosis was made when biopsy specimens
showed typical septate hyphae with dichotomous
branches; mucormycosis was diagnosed when
irregularly shaped, broad, non-septate hyphae with
branches occurring at right-angles were found. All
samples were cultured for bacteria and fungi. The
cross-tabulation parameters were calculated using
the standard Bayesian method.
Results
Between 1997 and 2002 we cared for 70 patients
with a clinical picture compatible with filamentous
fungal infection; of these patients 7 had mucormy-
cosis, 32 were defined as having a possible infection,
according to EORTC/ NIAID Mycoses Study Groups
criteria8 and 31 had probable or proven aspergillo-
sis. Mucormycosis was diagnosed by autopsy (3 cas-
es) and pulmonary biopsy (4 cases). Proven
aspergillosis was diagnosed by autopsy (3 cases), by
hepatic biopsy (3 cases), pulmonary biopsy (8 cas-
es) and pulmonary lobectomy (2 cases). Aspergillo-
sis was considered probable in 18 patients because
of a suggestive lung CT scan with sputum culture (2
cases), positivity for Aspergillus antigen (4 cases)
and positive BAL (12 cases). Among 32 cases of pos-
sible aspergillosis 25  diagnostic procedures (BAL in
20 patients and percutaneous lung biopsy in 5) were
negative (Figure 1). The following information was
evaluated: 1) duration of antifungal therapy prior
to biopsy; 2) results of histology and cultures; 3)
clinical course after percutaneous biopsy.
CT scanning was performed a median of 8 days
after the beginning of antifungal therapy and was
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repeated at the time of percutaneous biopsies. BAL
was done after a median of 10 days and percuta-
neous biopsies were taken, preferably from periph-
eral lesions, after  a median of 15 days (range 0-
90) of empirical antifungal treatment. Neutropenia
(<0.5×109/L) during the post-chemotherapy aplas-
tic phase lasted a median of 14 days (range 1-27)
The clinical characteristics and results of our
patients submitted to percutaneous pulmonary
biopsy are given in Table 1.
Twelve of the 17 patients had histologic demon-
stration of a fungal infection, an Aspergillus in 8
cases, and Mucorales in the other 4 cases. Biopsies
provided non-specific results in 4 cases; in 2 of
these, the clinical course and response to therapy
confirmed the diagnosis of mycosis. In the last case
bronchoalveolar carcinoma was found as a new
diagnosis . Overall, clinically useful information was
obtained in 13 of the 17 biopsies performed, 12
being diagnostic for fungal infection (accuracy
70.5%) and 1 for carcinoma. We determined the
accuracy of percutaneous lung biopsies in 2 cases by
subsequent surgical procedures (lobar resection);
histologic examination of the resected tissue mate-
rial confirmed the results of the biopsies. Of the 4
patients with negative biopsies, two had progres-
sive radiologic signs of mycosis. The sensitivity of
CT-guided percutaneous lung biopsy for the detec-
tion of fungal infections was 70.6% and its PPV was
100%. Cultures were positive in only 6 cases, all with
aspergillosis. Only one  patient had pneumothorax,
which required further treatment with tube inser-
tion. The biopsy procedure did not cause hemorrhage
or other complications in any  of the cases.
Twelve patients are alive and well after a medi-
an follow-up of 23 months (range 3-60); one
patient died because of leukemia, 3 patients died
because of progression of hematologic disease and
mycosis  and 1 because of carcinoma and leukemia.
Five patients underwent bone marrow transplan-
tation (1 allogeneic, 4 autologous) without recur-
rence of the fungal infection.
Percutaneous lung biopsy in aspergillosis and mucormycosis 
Table 1. Results of percutaneous lung biopsies in hematologic patients with negative BAL.
Age (yrs.) Hematologic Days of Chest Days of Results of biopsy Surgery Outcome
sex disease neutropenia CT antifungal therapy /histology
<100/mm3 before biopsy scan before biopsy
28/M AML 28 multiple nodules 15 Mucor alive after autoBMT
34/F Aplastic anemia 0 two nodules 20 Aspergillus alive
55/F AML 27 multiple nodules 7 Aspergillus alive after autoBMT
56/M AML 11 one cavitation 15 Aspergillus lobectomy alive after autoBMT
58/F AML 14 multiple cavitations 27 Aspergillus dead due to leukemia 
relapse and mycosis
40/M   NHL 0 one cavitation 0 Aspergillus alive
58/F AML 11 one cavitation 14 Mucor dead due to leukemia
60/F AML 12 multiple nodules 33 Mucor alive after autoBMT
54/M ALL 10 one cavitation 0 Mucor dead due to leukemia
and mycosis
36/F NHL 0 one cavitation 0 Aspergillus alive
47/M AML 20 two cavitations 22 Aspergillus lobectomy alive
64/F AML 14 multiple nodules 24 Aspergillus dead due to leukemia
and mycosis
35/F AML 17 multiple nodules 20 negative alive after alloBMT
43/F AML 15 multiple nodules 30 negative alive
63/M AML 16 multiple nodules 23 negative alive
49/F  AML 17 multiple nodules 13 negative alive
64/F AML 15 three nodules 90 carcinoma dead due to carcinoma
and leukemia
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Discussion
Aspergillosis and mucormycosis infections are
caused by filamentous fungi are usually very diffi-
cult to identify because the etiological pathogens
grow with difficulty even in appropriate media.
Serologic studies for diagnosing invasive aspergillo-
sis have been proposed but their results are still
under discussion. CT scans have proven to be very
useful for detecting specific signs of mycotic lesions
in the lung.9 In our experience  chest CT scans were
indispensable: 1) to orientate diagnosis by showing
the halo and/or air crescent signs, 2) to verify the
spread of infection, 3) to locate the position of fun-
gal lesions with respect to big vessels and to deter-
mine risk of hemoptysis and, finally 4) to choose
where percutaneous biopsy could be done. Unfor-
tunately radiologic signs alone define pulmonary
aspergillosis as possible and these are not able to
discriminate between different fungal species.
Bronchoalveolar lavage (BAL) is usually performed
in neutropenic patients if the radiologic picture sug-
gests a fungal infection, but the sensitivity of this
method’s detection of invasive aspergillosis in a
leukemic population is <50%5 confirmed by a recent
report from Caillot et al.3 and also by our own expe-
rience.4 It should, however, be noted that we per-
formed BAL a median of 10 days after the beginning
of empiric antifungal therapy, which could have
caused our negative results. Regarding mucor-
mycosis, ante-mortem diagnosis in neutropenic
patients is unusual because blood cultures are
invariably negative; bronchial washings have yield-
ed hyphal forms only on rare occasions. Berns et
al.10 noted that a mucoraceous fungus was recov-
ered from only 1 of 1,440 consecutive bronchial
brushing specimens, but that 1 instance was an
autopsy-proven case of mucormycosis. Aspergillus is
a common saprophyte and  a positive culture is not
proof of infection. Hence the gold standard is myco-
logic and/or histologic evidence of tissue invasion.
Until now percutaneous pulmonary biopsy has
rarely been performed in hematologic patients;  spo-
radic cases and rare series are described.6,11 More
often, this method has been used successfully  to
diagnose pulmonary neoplasms and to identify pul-
monary infections in radiologically suspicious nod-
ules.12 In our experience the sensitivity (70.6%) of
percutaneous pulmonary biopsy was high , even in
patients who had been receiving antifungal thera-
py for many days; in this case it is possible to obtain
false negative results , which have also been report-
ed using open–lung biopsy.13 On the other hand, it
is usual to begin antifungal therapy in an empirical
manner in leukemic patients in the post-chemother-
apy aplastic phase, because fungal infections in such
patients are very aggressive and mortality is very
high.2 As these patients also  have severe thrombo-
cytopenia, it is necessary to wait for the platelet
count to increase (> 50×109/L) before attempting
invasive procedures. Despite this wait, which in our
experience was  a median of 15 days, biopsy showed
a diagnostic result in a high number of cases
(76.4%), and allowed aspergillosis and mucormyco-
sis to be discriminated. This histologic discrimination
was very important for our patients because Muco-
rales spp. are usually resistant to azoles and
echinocandins, so only amphotericin B can be used
as treatment and secondary prophylaxis during
transplant procedures. Mucormycosis was not rare
in our experience14 and is probably generally under-
evaluated because the clinical pictures of this infec-
tion and aspergillosis are similar.
A major advantage of percutaneous lung biopsy is
the speed of the procedure, which provides an
immediate diagnosis and usually does not have
important side-effects. Pneumothorax15 and fatal
pulmonary hemorrhage16 have, however, been pre-
viously described. The increased risk of morbidity
when performing an invasive procedure in a com-
promised patient is obvious, particularly in leukemic
patients with a low number of platelets.   Never-
theless, in our patients this procedure, always per-
formed when the platelet count was > 50×109/L,
was well tolerated and only one  patient had pneu-
mothorax (6%) without severe complications. Dis-
semination of the fungal infection has also been
described after transthoracic lung biopsy;17 howev-
er we usually continue empirical antifungal thera-
py  until confirmation of fungal infection and/or dis-
appearance of lesions in the absence of a certain
diagnosis; all the biopsies were done under anti-
fungal therapy and no dissemination was seen.
Two patients underwent pulmonary lobectomy,
one because of hemoptysis and the other before
transplant; biopsy results are certainly useful also
for the surgeon when deciding on a possible pul-
monary resection,11 which is often necessary in cas-
es of hemoptysis and/or when big cavitations are
present in scheduled bone marrow recipients. In
fact fungal relapses are possible in bone marrow
transplant recipients both during the early post-
transplant neutropenic phase and if acute and
chronic graft-versus-host disease occurs.18
In conclusion, an accurate diagnosis of fungal
species allows the correct duration and choice of
antimycotic therapy to be planned, and an ade-
quate secondary prophylaxis to be given both dur-
ing subsequent chemotherapy courses and in the
post-transplant period, in particular in patients
who have undergone allogeneic  and one fully mis-
matched HLA haplotype transplant,19 who are con-
sidered at very high risk of fungal infection.
A. Nosari et al.
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